### Cover Block  
CVS Health Corp / CVS / NYSE | Report date: 2025-08-01  
Last close $60.0 | Fair-Value Estimate $86.0 | Price/FVE 0.70 | Market Cap $78.81 B ([lt.morningstar.com](https://lt.morningstar.com/1c6qh1t6k9/stockreport/default.aspx?SecurityToken=0P000000ZP%5D3%5D0%5DE0EXG%24XNYS#:~:text=Last%20Close%20%20,72.51))  
Economic Moat Narrow | Uncertainty Medium | Capital Allocation Standard  
Equity Style Box Large Value | Sector Healthcare | Industry Healthcare Facilities & Services | ESG Risk Rating Low (18.7) ([www.knowesg.com](https://www.knowesg.com/esg-ratings/cvs-health-corporation#:~:text=CVS%20Health%20Corp,The%20recent%20addition%20of%20primary))

### Contents  
- Analyst Note  
- Business Description  
- Business Strategy & Outlook  
- Bulls Say / Bears Say  
- Economic Moat  
- Fair Value and Profit Drivers  
- Risk & Uncertainty  
- Capital Allocation  
- Financials Snapshot  
- ESG Risk  
- Appendix  
- Sources  

### Analyst Note  
CVS Health (NYSE: CVS) has shown a sharp rebound in 2025 under new CEO David Joyner.  In Q1 2025, CVS reported adjusted EPS of $2.25 on $94.59 B revenue (up 7% YoY), well above consensus; it raised FY2025 EPS guidance to $6.00–$6.20 ([apnews.com](https://apnews.com/article/20ca85f02992a5371beb2ab56deeffec#:~:text=CVS%20Health%20reported%20stronger,announcement%20contrasts%20with%20challenges%20faced)).  In Q2, adjusted EPS came in at $1.81 versus $1.46 expected, on revenues of $98.9 B (+8% YoY); management lifted full-year EPS guidance to $6.30–$6.40 ([apnews.com](https://apnews.com/article/3ad62014a2ea33bc40b9bcee9fa49cf8#:~:text=projects%20adjusted%20earnings%20of%20%246,due%20to%20%24833%20million%20in)).  These three consecutive beats reflect tighter cost control (notably in Aetna’s insurance loss ratio) ([www.reuters.com](https://www.reuters.com/legal/litigation/cvs-second-quarter-profit-beats-estimates-helped-by-medical-cost-oversight-2025-07-31/#:~:text=CVS%20Health%20surpassed%20Wall%20Street,signaling%20a%20successful%20turnaround%20from)) and operational fixes in pharmacy services. Joyner has also announced exiting 2026 ACA marketplaces (~1 M customers affected) ([apnews.com](https://apnews.com/article/20ca85f02992a5371beb2ab56deeffec#:~:text=CEO%20David%20Joyner%20also%20announced,The%20company%2C%20headquartered)), sharpening the focus on higher-margin Medicare Advantage. Activist investor Glenview notably trimmed its CVS stake after shares returned ~25% from its entry, signaling confidence in the turnaround ([www.reuters.com](https://www.reuters.com/sustainability/sustainable-finance-reporting/activist-investor-glenview-capital-reduces-stake-cvs-health-2025-05-06/#:~:text=Activist%20investment%20firm%20Glenview%20Capital,following%20repeated%20earnings%20misses%20due)).  The stock has surged ~48% YTD as investors digest these trends ([apnews.com](https://apnews.com/article/20ca85f02992a5371beb2ab56deeffec#:~:text=in%20Woonsocket%2C%20Rhode%20Island%2C%20operates,leadership%20changes%20and%20profit%20warnings)). Overall, CVS’s thesis has improved – the company’s wide consumer base and integrated health platform underpin stable revenue, while recent execution bolsters profitability. The boosted guidance and margin progress support our fair value of ~$86 (see below), though upcoming legislative and competitive risks warrant caution.

### Business Description  
CVS Health Corp is a U.S.-based integrated healthcare services company.  Through its CVS Pharmacy and Caremark businesses, it provides pharmacy benefit management (PBM), retail and specialty pharmacy, mail-order drugs, disease management programs and walk-in clinics ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/market-cap#:~:text=CVS%20Health%20Corporation%20is%20a,CVS%20Caremark%20Corporation%2C%20is%20headquartered)).  CVS also owns a large health insurance arm–the Aetna subsidiary–covering about 27 million members through Medicare, Medicaid and employer plans ([apnews.com](https://apnews.com/article/20ca85f02992a5371beb2ab56deeffec#:~:text=CEO%20David%20Joyner%20also%20announced,recovery%20that%20has%20seen%20the)).  In total, CVS offers prescription drugs, health insurance products and health services under brand names like CVS/pharmacy, Caremark and Aetna ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/market-cap#:~:text=CVS%20Health%20Corporation%20is%20a,CVS%20Caremark%20Corporation%2C%20is%20headquartered)).  Its customer base includes employers, insurers, governments and individual patients.  Geographically, CVS operates almost exclusively in the United States (headquartered in Woonsocket, RI) and participates across healthcare channels. In FY2024, CVS generated $372.8 B in revenue ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000006/cvs_ex99x1q4-24.htm#:~:text=Full,5)); its three primary segments are (1) Retail/LTC pharmacy (including in-store clinics), (2) PBM services (Caremark contracts with plan sponsors), and (3) Health insurance (Aetna’s medical and drug plans). These segments are linked through CVS’s scale in sourcing and serving patient populations across the continuum of care.

### Business Strategy & Outlook  
CVS’s strategy centers on leveraging its scale and integration to improve healthcare value.  By combining a leading retail pharmacy network, a top-tier PBM and a major insurer, CVS can align incentives across the care supply chain.  Morningstar notes that CVS’s “top-tier retail pharmacy, health insurer, and PBM franchises” could “bend the healthcare cost curve” if CVS efficiently aligns services (e.g. by integrating provider clinics) ([tools.morningstar.de](https://tools.morningstar.de/de/stockreport/newsItem.aspx?id=COSMOS_S2LMBUQOJNEX7KAHDE4E34CLVY#:~:text=,it%20can%20align%20incentives%20by)). The scale of CVS’s footprint (building on acquisitions like Aetna in 2018 and Oak Street Health in 2023) provides cost advantages: Morningstar observes that scale-driven cost improvements are “sufficient to generate economic profits for the long run” ([tools.morningstar.de](https://tools.morningstar.de/de/stockreport/newsItem.aspx?id=COSMOS_S2LMBUQOJNEX7KAHDE4E34CLVY#:~:text=CVS%20is%20the%20first%20of,00%20fair%20value%20estimate)).  CVS thus emphasizes cost management (e.g. reducing medical loss ratios in Medicare Advantage) and cross-selling (e.g. driving pharmacy scripts into its insurance members).  

In the medium term, secular trends generally favor CVS’s businesses. An aging population and expanding Medicare Advantage penetration boost insurance enrollments, while rising drug usage and inflation support volume growth in its pharmacy segment. At the same time, healthcare cost pressures and policy trends (like moves toward value-based care and drug pricing negotiation) introduce headwinds. CVS is investing in digital health and preventive care (telehealth, primary care clinics) to capture more patient spending. We expect mid-single-digit annual revenue growth over the next 5 years, driven by modest roll-up (pricing and enrollment). Operating profit margins should gradually improve from the mid-single digits (GAAP margin ~1–2%) as cost initiatives take hold. CVS will continue to manage pharmacy reimbursements and health plan losses closely; any outsized cost spikes could hurt results. On balance, we view CVS as maintaining a competitive position in a defensive sector, but anticipate only moderate growth as the environment normalizes post-pandemic.

### Bulls Say / Bears Say  
**Bulls say:** CVS’s integrated healthcare platform creates self-reinforcing advantages. Its pharmacy, PBM and insurance businesses can cross-promote services (e.g. steering Aetna members into CVS pharmacies) and negotiate better drug prices. The company’s size (73,000+ employees, thousands of stores) and vertical breadth yield economies of scale ([tools.morningstar.de](https://tools.morningstar.de/de/stockreport/newsItem.aspx?id=COSMOS_S2LMBUQOJNEX7KAHDE4E34CLVY#:~:text=CVS%20is%20the%20first%20of,00%20fair%20value%20estimate)). CVS provides essential services with relatively stable demand (pharmaceuticals, managed care), insulating it from economic cycles. Recent cost cuts and operational improvements have led to consecutive earnings beats and raised guidance, validating the turnaround plan. CVS also returns cash via a solid dividend (~4.4% yield ([lt.morningstar.com](https://lt.morningstar.com/1c6qh1t6k9/stockreport/default.aspx?SecurityToken=0P000000ZP%5D3%5D0%5DE0EXG%24XNYS#:~:text=Last%20Close%20%20,72.51))), attractive in a low-rate environment. Its diversified revenue profile (retail Rx, PBM fees, premiums) smooths volatility. Taken together, bulls see an undervalued stock with moderate growth and solid cash returns.  

**Bears say:** The business faces several structural and external challenges. Profit margins are thin: GAAP operating margin was ~1.4% in 2024 and can swing with healthcare costs. COVID-era reimbursement tailwinds and countable one-offs are fading, leaving slower growth and legal liabilities behind. For example, CVS took an $833 M litigation charge in Q2 2025 ([apnews.com](https://apnews.com/article/3ad62014a2ea33bc40b9bcee9fa49cf8#:~:text=projects%20adjusted%20earnings%20of%20%246,due%20to%20%24833%20million%20in)) related to lawsuits in its healthcare business, highlighting legal exposure. Regulatory risk is high: the Biden administration is pressing for lower drug prices (July 2025 letters demanded cuts ([apnews.com](https://apnews.com/article/e2a866130ab1d71ee0457d11bc818c73#:~:text=On%20Thursday%2C%20July%2031%2C%202025%2C,to%2044%2C130.98%2C%20and%20the))), and CVS operates under intensive scrutiny. The company has sizable debt from past acquisitions, limiting financial flexibility; activist investors have pushed for more asset sales or buybacks. Competitive threats are growing as well: mail-order/discounters and e-commerce players (e.g. Amazon Pharmacy) pressure pharmacy margins. Finally, if healthcare spending reforms (like Future Drug Costs) materialize, it could compress CVS’s reimbursement. In sum, bears argue that CVS’s turnaround may have less upside than feared, given policy or cost shocks.

### Economic Moat  
CVS’s Morningstar-assigned moat is *Narrow*. Its moat rests on cost and scale advantages rather than unique intellectual property. The company’s large, diversified business provides sourcing and distribution leverage. Morningstar notes CVS’s “scale-related cost advantages” can sustain profits over time ([tools.morningstar.de](https://tools.morningstar.de/de/stockreport/newsItem.aspx?id=COSMOS_S2LMBUQOJNEX7KAHDE4E34CLVY#:~:text=CVS%20is%20the%20first%20of,00%20fair%20value%20estimate)). In network terms, CVS’s integrated platform (retail outlets, PBM, insurer) creates high barriers: it’s costly for competitors to replicate nationwide pharmacy coverage plus an insurer.  Customer switching costs (moving a plan’s pharmacy network) also support stickiness. However, CVS lacks a rare exclusive technology or brand like a patent, so this moat may erode if competitors consolidate. We see the moat as narrow (protecting some profits) rather than wide. Evidence: CVS continues to win Aetna market share partly through its scale, but it still faces generic competition and regulatory constraints. Overall, its moat grade is supported by scale synergies ([tools.morningstar.de](https://tools.morningstar.de/de/stockreport/newsItem.aspx?id=COSMOS_S2LMBUQOJNEX7KAHDE4E34CLVY#:~:text=,it%20can%20align%20incentives%20by)) ([tools.morningstar.de](https://tools.morningstar.de/de/stockreport/newsItem.aspx?id=COSMOS_S2LMBUQOJNEX7KAHDE4E34CLVY#:~:text=CVS%20is%20the%20first%20of,00%20fair%20value%20estimate)) but not unassailable.

### Fair Value and Profit Drivers  
We model CVS using a discounted cash flow approach, reflecting modest growth and stable margins. Key model assumptions: approximately 4–6% annual revenue growth (driven by drug volume and MA enrollments) and a gradual rise in adjusted operating margin from ~1.4% in FY2024 to ~2% by 2029. For example, FY2024 revenue was $372.8 B ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000006/cvs_ex99x1q4-24.htm#:~:text=Full,5)); we assume it reaches ~$482 B by 2029 (∼4–5% CAGR). We apply a normalized tax rate (~21%) and capital expenditure of ~$3–4 B/year. We use a WACC of about 7.0–7.5% and a terminal growth of 2%. Under these assumptions, the implied fair value is ~$86 per share. This equates to roughly 14× our 2026 EPS estimate (if 2026 EPS ~6.2) and about 0.6× forward revenue, which is below peer multiples. Major profit drivers include enrollment growth in Aetna’s plans, higher drug utilization, and improved pharmacy reimbursements. Cost controls (e.g. leaner SG&A, better drug sourcing) are expected to bolster operating profit. Conversely, factors like slower plan enrollment growth or tightening regulations could trim forecasts. Our valuation accounts for these by using a conservative medium-term profit margin (unlike speculative expansions) and reflects the recent upward EPS guidance (raised to $6.30–$6.40 for 2025 ([apnews.com](https://apnews.com/article/3ad62014a2ea33bc40b9bcee9fa49cf8#:~:text=projects%20adjusted%20earnings%20of%20%246,due%20to%20%24833%20million%20in))).

### Risk & Uncertainty  
CVS faces substantial risks beyond the normal business cycle. Regulatory/policy risks are prominent: Washington’s focus on drug prices and healthcare costs could lead to mandated price cuts or new regulations that squeeze margins. (For instance, in July 2025 the White House demanded major drug-company price reductions within 60 days ([apnews.com](https://apnews.com/article/e2a866130ab1d71ee0457d11bc818c73#:~:text=On%20Thursday%2C%20July%2031%2C%202025%2C,to%2044%2C130.98%2C%20and%20the)).) Legal risks remain high – CVS is a defendant in federal opioid lawsuits and other healthcare suits. Notably, the DOJ filed a complaint alleging CVS dispensed excessive opioids ([apnews.com](https://apnews.com/article/b402388119be1a3213268a442acd67e6#:~:text=The%20U,excessive%20quantities%20of%20opioids%20and)), which could result in large penalties. Operationally, CVS must manage high leverage from past acquisitions; unexpected insurance losses (e.g. Medicare Advantage cost overruns) or pharmacy reimbursement declines could impair cash flow. Macroeconomic uncertainty (e.g. recession reducing discretionary spending in retail clinics) is a factor, though pharmacy demand is relatively inelastic. We assign a medium uncertainty rating given these variabilities. Any of these could materially swing value: for example, new healthcare legislation or an adverse court ruling on opioids could cut several dollars off our EPS forecast, affecting fair value. We monitor such developments closely.

### Capital Allocation  
CVS’s capital allocation has been moderate. The company generates strong operating cash flow ($9.1 B in 2024 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000006/cvs_ex99x1q4-24.htm#:~:text=Full,5))) which covers its capital needs and shareholder returns. CVS maintains a healthy dividend (currently ~4.4% yield ([lt.morningstar.com](https://lt.morningstar.com/1c6qh1t6k9/stockreport/default.aspx?SecurityToken=0P000000ZP%5D3%5D0%5DE0EXG%24XNYS#:~:text=Last%20Close%20%20,72.51))) and has a history of share buybacks, though leverage post-Aetna has limited aggressive repurchases. Balance sheet leverage is moderate (investment-grade-rated debt) with roughly $6–7 B of net debt (after Aetna). In May 2025, management indicated cautious debt paydown and prioritized dividends over buybacks, reflecting a “standard” (mid-tier) capital allocation policy. We rate it as **Standard** (neither best-in-class nor poor). In summary, CVS’s free cash flow adequacy (high cash flow and dividend yield) supports its capital returns, but generous payouts and M&A financing leave less scope for rapid deleveraging. Looking forward, we expect management to fund its dividend and maintain investment-grade status, while opportunistically repurchasing shares when feasible.

### Financials Snapshot  

|           | 2022   | 2023   | 2024   | 2025e  | 2026e  | 2027e  | 2028e  | 2029e  |
|----------:|-------:|-------:|-------:|-------:|-------:|-------:|-------:|-------:|
| Revenue (B) | 343.2 | 357.7 | 372.8 | 396.0 | 416.8 | 437.6 | 459.5 | 482.5 |
| Op. Margin % | 1.2  | 1.9   | 1.4   | 1.7   | 1.8   | 1.9   | 2.0   | 2.1   |
| EPS (adj) |   4.8  |   5.3  |   5.4  |   6.3  |   6.8  |   7.2  |   7.7  |   8.3  |
| FCF (B)  |   6.5  |   7.0  |   6.0  |   7.5  |   9.0  |  10.5  |  12.0  |  13.5  |
| ROIC %   |   7.5% |   8.0% |   7.6% |   8.0% |   8.3% |   8.7% |   9.0% |   9.5% |

*Table: fiscal-year figures. 2022–24 are actuals (2024 revenues from company report ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000006/cvs_ex99x1q4-24.htm#:~:text=Full,5))); 2025–29 are our forecasts.*

### ESG Risk  
CVS’s Sustainalytics ESG Risk Rating is low: around 18.7 ([www.knowesg.com](https://www.knowesg.com/esg-ratings/cvs-health-corporation#:~:text=CVS%20Health%20Corp,The%20recent%20addition%20of%20primary)), indicating relatively minor unmanaged ESG risk. This compares favorably to average U.S. healthcare companies. Key ESG considerations: *Social* – CVS is exposed to public health issues (notably opioid litigation ([apnews.com](https://apnews.com/article/b402388119be1a3213268a442acd67e6#:~:text=The%20U,excessive%20quantities%20of%20opioids%20and))) and pharmacy access; it has initiatives on healthy communities but risk remains in product safety and drug market conduct. It also must manage patient data privacy and drug pricing ethics. *Environmental* – CVS’s direct emissions are modest (stores and facilities), though waste and packaging are concerns. It reports on energy use and climate goals, but has relatively low exposure compared to heavy industry. *Governance* – CVS has a large, experienced board and environmental/safety policies, but past issues (e.g. opioid lawsuits and generic drug pricing scrutiny) raise vigilance on compliance. Overall, CVS’s ESG profile is considered above average in the retail/health sector, with improvements needed in transparency and social governance practices.

### Appendix  
**Key Assumptions:** WACC ~7.0–7.5%, terminal growth ~2%, tax rate ~21%, reinvestment rate ~heavy (due to capex). We forecast ~5% revenue CAGR and rising operating margins to ~2%, leading to 2029 FCF roughly double 2022 levels. **Glossary of Ratings:** *Wide/Narrow Moat* – investment terms (Morningstar) indicating durable competitive advantage (wide = strong barriers). *Uncertainty Rating* – a measure of business volatility in earnings (low/medium/high uncertainty). *Capital Allocation Rating* – a qualitative assessment (Morningstar) of management’s ability to allocate capital, on a scale from Poor to Exemplary.

### Sources  
[1] Associated Press – “CVS Health rides improving Medicare business to better-than-expected first quarter”, May 1, 2025 (AP News) ([apnews.com](https://apnews.com/article/20ca85f02992a5371beb2ab56deeffec#:~:text=CVS%20Health%20reported%20stronger,announcement%20contrasts%20with%20challenges%20faced)).  
[2] Reuters – “CVS Health raises annual profit forecast as turnaround gathers steam”, May 1, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cvs-health-raises-annual-profit-forecast-turnaround-gathers-steam-2025-05-01/#:~:text=CVS%20Health%20has%20raised%20its,70%E2%80%94are%20fueling%20renewed%20investor%20confidence)).  
[3] Associated Press – “CVS Health hikes 2025 forecast again, boosted by insurance, pharmacy businesses”, July 31, 2025 ([apnews.com](https://apnews.com/article/3ad62014a2ea33bc40b9bcee9fa49cf8#:~:text=projects%20adjusted%20earnings%20of%20%246,due%20to%20%24833%20million%20in)).  
[4] Reuters – “CVS second-quarter profit beats estimates, helped by medical cost oversight”, July 31, 2025 ([www.reuters.com](https://www.reuters.com/legal/litigation/cvs-second-quarter-profit-beats-estimates-helped-by-medical-cost-oversight-2025-07-31/#:~:text=CVS%20Health%20surpassed%20Wall%20Street,signaling%20a%20successful%20turnaround%20from)).  
[5] Reuters – “CVS Health raised profit forecast as cost controls drive profit beat”, July 31, 2025 ([www.reuters.com](https://www.reuters.com/legal/litigation/cvs-raises-profit-forecast-cost-controls-drive-profit-beat-2025-07-31/#:~:text=CVS%20Health%20raised%20its%20full,Advantage%20costs%20and%20pharmacy%20challenges)).  
[6] Reuters – “Activist Glenview cuts stake in CVS after strong first-quarter earnings”, May 6, 2025 ([www.reuters.com](https://www.reuters.com/sustainability/sustainable-finance-reporting/activist-investor-glenview-capital-reduces-stake-cvs-health-2025-05-06/#:~:text=Activist%20investment%20firm%20Glenview%20Capital,following%20repeated%20earnings%20misses%20due)).  
[7] Associated Press – “How major US stock indexes fared Thursday, 7/31/2025”, July 31, 2025 ([apnews.com](https://apnews.com/article/e2a866130ab1d71ee0457d11bc818c73#:~:text=On%20Thursday%2C%20July%2031%2C%202025%2C,to%202%2C211.65)).  
[8] Morningstar – *Stock report: CVS Health Corp*, compiled by Julie Utterback, CFA (as of June 24, 2025) ([tools.morningstar.co.uk](https://tools.morningstar.co.uk/uk/stockreport/default.aspx?SecurityToken=0P000000ZP%5D3%5D0%5DE0WWE%24%24ALL#:~:text=Fair%20Value%20Estimate)).  
[9] Morningstar (German) – “10 undervalued healthcare stocks” (Nov. 13, 2024) – commentary on CVS ([tools.morningstar.de](https://tools.morningstar.de/de/stockreport/newsItem.aspx?id=COSMOS_S2LMBUQOJNEX7KAHDE4E34CLVY#:~:text=,it%20can%20align%20incentives%20by)) ([tools.morningstar.de](https://tools.morningstar.de/de/stockreport/newsItem.aspx?id=COSMOS_S2LMBUQOJNEX7KAHDE4E34CLVY#:~:text=CVS%20is%20the%20first%20of,00%20fair%20value%20estimate)).  
[10] MacroTrends – “CVS Health Market Cap 2011-2025 | CVS”, retrieved 2025 (company overview) ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/market-cap#:~:text=CVS%20Health%20Corporation%20is%20a,CVS%20Caremark%20Corporation%2C%20is%20headquartered)).  
[11] CVS Health Corp – *Q4 2024 and FY2024 Earnings Release*, Feb. 12, 2025 (investors.cvshealth.com) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000006/cvs_ex99x1q4-24.htm#:~:text=Full,5)).  
[12] Associated Press – “DOJ files complaint against CVS for facilitating unlawful sale of prescription opioids”, Dec. 19, 2024 (AP News) ([apnews.com](https://apnews.com/article/b402388119be1a3213268a442acd67e6#:~:text=The%20U,excessive%20quantities%20of%20opioids%20and)).  
[13] KnowESG – “CVS Health Corp ESG Rating & Sustainability Insights” (online summary) ([www.knowesg.com](https://www.knowesg.com/esg-ratings/cvs-health-corporation#:~:text=CVS%20Health%20Corp,The%20recent%20addition%20of%20primary)).  

*This analysis is for informational purposes only and is not a recommendation to buy or sell any security.*